Considering the interplay between systemic immune cell ratios and the tumor microenvironment, particularly their association with the NOS2/ARG1 axis and tumor-infiltrating lymphocytes, we next explored the clinical relevance of these markers. This evidence concerns the gene NOS2 and neoplasm.